drugset
drugset / Trial / NCT00437632

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

NCT00437632 ↗

Phase 1 Completed 104 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will evaluate the safety, tolerability and pharmacokinetics of repeat doses of GSK598809 in healthy volunteers.

Timeline

Start
2007-03-01
Primary completion
2008-08-22
Completion
2008-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK598809 Unknown 10 mg Oral
Subject GSK598809 Unknown 25 mg Oral
Subject GSK598809 Unknown 40 mg Oral
Subject GSK598809 Unknown 75 mg Oral
Subject GSK598809 Unknown 120 mg Oral
Subject GSK598809 Unknown 175 mg Oral
Background Caffeine Small molecule 100 mg Oral

Indications

substance dependence